The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I keep adding. To buy at moment is 23.9 via HL.
Yes Aber we are much further ahead but funding needs resolving at very least to take us to end of phase 1a.
Fearg mentioned 100 investors here at 3000 each. I don't have a problem with that.
Regards
I see no reason as to why there should be resignations. A reduction of salaries yes.
They need to resolve the funding issue.
Sareum plan to licence at end of preclinical to early clinical. We sit right in the middle and await data results.
If the data is not get then end of Sareum
If the data is topline ie good safety profile and biomarker data then put a value on 1801
You cannot realistically assign a relevant value until you have the data and its in depth analysis.
You need assurance of satisfactory safety profile and to further enhance biomarker data
The SP had declined drastically with the knockback from the MHRA
Most likely and indicative of this is the cautious start of 5mg per day and ascending dose up to 300g per day. Based primarily on Jak1 Jak2 inhibitors which have far greater unwantrd off target effects.
I did read a comment regarding maybe extra testing to establish an MTD
That is most definitely out of the question as cannot be established in healthy human beings.
300 mg per day is less than a third of the anticipated maximum therapeutic benefit.
Preclinical testing and safety data carried out dosing at 30 times maximum treatment level.
No serious side effects were observed to indicate that a MTD had been established.
Although normally a requirement to have an established MTD before any clinical trial of 5his nature can be granted however it has been such that in the past the attainment of reaching 30 times therapeutic dose was considered acceptable in the absence of a non established MTD.
Good evening again HbD.
I share the same thoughts as yourself with regards to data.
Would you as an interested party invest in any form of a compound until you have data confirmation that the compound has a satisfactory profile to be taken to the next phase of clinical trial?
Until such confirmation is received ot is very unlikely that an interested party would commit themselves. Expectation is one thing but satisfactory data is the proof of the pudding.
Safety data ( and l note the use of the term top notch) is expected by Sareum in Q2.
In addition to safety data, basically LADMET, Pk profile, tolerability there will also be extremely important biomarker data.
Biomarker data will give areas of treatment that SDC1801 should show the most potential in.
A list not exhaustive below.
person may have more than one autoimmune disorder at the same time. Common autoimmune disorders include:
Addison disease
Celiac disease - sprue (gluten-sensitive enteropathy)
Dermatomyositis
Graves disease
Hashimoto thyroiditis
Inflammatory bowel disease (Crohn disease, ulcerative colitis)
Multiple sclerosis
Myasthenia gravis
Pernicious anemia
Reactive arthritis
Rheumatoid arthritis
Sjögren syndrome
Systemic lupus erythematosus (lupus)
Type I diabetes
We don't need the whole of the above just 1 or 2 to start with in addition to Psoriasis.
For an interested party they will need the biomarker data and interpretation of.
Once confirmation of biomarker data we can move forward.
All about the data.
In 2011 Sareum jumped over 1100% in one day on good preclinical trial data of which we had only 27.5%.
As it sits SDC1801 in its current stages of development is worth considerably more than the current market cap. It will be worth considerably more on satisfactory data than it is now.
Your last paragraph regarding RF l agree fully with.
One thing we can all agree on is without RF we would not be in the situation we are now.
The most important glass half full says it has enabled us to progress to clinical trial.
The downside is the extreme negative impact it has had on the SP
The SP is recoverable it just needs satisfactory data that leads to good investment.
Regards
I am working in Kent at the moment and would be pleased to meet up for a beer at some time in the not too distant future PC1954.
Gunner68. Appreciate your response, however at one time finance was easy to come by and unfortunately that is no longer the case.
An agreement in some form another with an interested party is one route, but this in turn is not straight forward as dependant on what and who the interested party or parties intend on doing with 1801 and how much funds they have themselves for further development and/or how much they are prepared to pay upfront at which stage of phase completion reflects in increased value of 1801.
For example a 10 to 20% ownership of sareum for circa 2 to 4 million advance.
They will have options and it is down to BoD took at the best or least damaging way forward as some would chose to see it.
Regards.
After the MHRA debacle Sareum overcame this.
Most likely and verging on definite reason being the non establishment of a maximum tolerated dose.
The aussies give them their due assigned a cautious dosage derived from Compounds such as Baricitinib a Jak 1 Jak 2 inhibitor along with their associated safety profile risk due to off target effects.
We are not Jak1 Jak2.
We are Tyk2 Jak1 with the selectivity of around 80% of Tyk2 over Jak1.
Later generation inhibitors can be formulated to have greater selectivity over other Jaks.
Keep the faith and regards to all.
Not the most money generating RNS that is for sure.
However, we must look at the positives.
Securing an alternative form of finance should relieve Sareum of the continuing stifling and reduction of the SP. That providing we do not enter a similar type of agreement.
What is required at the moment is 300k, most likely to guarantee us to end of phase 1a data results.
The data results are the make or break of the company. No amount of money injected into the company or current market cap will make a blind bit of difference should the 1801 compound data prove to be unsatisfactory. It would be disastrous.
The other side of the coin is that should tha data be satisfactory then a degree of risk is removed.
Subsequently this will have a positive effect on the SP but in the current financial climate and with RF still having the ability to sell Sareum shares this will without doubt stem any large sustainable SP rise until more positive information is released.
300k in the grand arena of early and mid stage of development is very little and very unlikely that this cannot be raised.
What will concern investors is the amount of dilution that may arise when attempting to raise more funding for later stage.
Sareum in my belief have the ability via entering into an agreement with current interested parties.
The less data that these parties have on compound safety and efficacy the greater share they will want of either the company or the compound or compounds.
The 300k should present no serious problem especially as early toxicity results proving favourable.
As l put in early post this am ot is all about eeking the finance from RF and getting to take us to end of at least phase 1a data results.
More shown buys against sells.
We have around 71 million shares.
3.5 billion in old money shares putting an old money price of 0.5p per share of which we are much much further down the line as now in clinical trial.
RF finance was not good but it allowed the continuation of 1801 to enter into clinical trial following the shenanigans with the MHRA which in addition to considerable cost also resulted on a delay pushing close to a year.
Sareum overcame this problem and no reason as to why they cannot overcome the current predicament.
How much was paid for Deucravacitinib?
We are in a similar arena with a product that has the potential to have greater efficacy in some Indications.
4 billion for Deucravacitinib and if we look at the often quoted 10% success rate to approval and commercialisation that would give us a figure of 400 million.
Not wishing the above to be taken as an exact figure but more indicative of the reduction in risk against rising compound values.
On the brighter side of this we have a greater than this 1 in 10 success factor as early stage safety profile satisfactory.
We have the approval of a TYK2 inhibitor for use in the clinic, ( reassurance due to Deucravacitinib)
A very realistic post Leggster.
The further we progress then so does the element if risk reduce.
For what we have seen so far is satisfactory SAD and await the MAD results and the most important associated data.
Should we take the rapid progress of going from SAD to MAD as an indication of 1801 safety indication ot points very heavily to a more than favourable outcome for end of phase 1a data.
Biomarker data will then become the next important stepping stone as will indicate the potential areas of most efficacy in disease control.
Psoriasis is but one indication of which good efficacy is nigh guaranteed.
TM many moons ago stated in an interview with Andrew Scott that Deucracitinib showed good safety profile and good results in Psoriasis which Sareum found encouraging but at the same time believed 1801 could achieve greater efficacy due to the dual approach of Tyk2 and Jak1.
Once data is realised from Phase l a then the so called interested parties can negotiate some sort of collaboration in one form or another.
I should think that there is a trade off between how long the RF finance can be eeked out against full trial data review.
In this instance there will be expressions of interest as of now with early stage data proving favourable, against later data, whereby biomarker data will provide greater scope as to which Indications 1801 look very promising in, significantly increasing the value of the compound once the likelihood of most successful treatment areas are established.
Informal discussions will continue to be ongoing until the release of safety or safety and biomarker data are realised. The latter giving the compound a greater value.
Should we progress to phase 1b and l rill use the term of highly competitive efficacy in Psoriasis then this will dramatically increase value of 1801.
Of thst there can be of little doubt.
One down side of early phase on licence is smaller upfront payment with higher backend milestones.
All we are looking for to move from phase 1a to phase 1b completion is around 3 million max which is peanuts to what we have and achievements so far.
Ramble on a bit as usual but am like thst sfter night shifts
Regards to all.
We also need take into account that phase 2 clinical trial gave good results in preventing disease progression in patients with advanced stages of cancer that had previously been treated to which little hope remained.
Given at an earlier stage would the results been significantly better?
In addition there were no clinical trials of triple combo with either PARPi or PD-1 that researchers had been calling out for.
I would like to think we will get an update by first week of April on this.
Regards
Not too dissimilar in combo partners to our 737. We should be in clinical use by now after nothing for approacing 5 years.
https://pubmed.ncbi.nlm.nih.gov/38402224/
Regards
WHOOPS NO LINK!
https://pubmed.ncbi.nlm.nih.gov/35078817/
Apologies.
I don't think our 737 is of any use in this line of treatment 007.
It is in a sense very similar to our 737.
In combo therapy here good results with Chemo and Parpi. Not too dissimilar from our own.
Take at look at link below gor more in depth info.
Regards